A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a ...
ALS medication AMX0114 has been well tolerated in early clinical testing, and is now moving to a second, higher-dose trial ...
Hosted on MSN
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
The MIROCALS randomized clinical trial involved research institutions, medical centers and logistical organizations across the UK, France, Italy, Sweden and Ireland. A team at Queen Mary, University ...
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense "This exciting Phase 2b trial data underscores PrimeC's ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: ...
SAN FRANCISCO--(BUSINESS WIRE)--Unlearn ®, a pioneering artificial intelligence company, today announced a groundbreaking partnership with German-based APST Research (APST), a leading platform for ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback